Taysha Gene Therapies, Inc.

Fundamentals3.5
Price Action5.0
News Sentiment5.0
AI Rating
5.0

Key Drivers

  • Strong liquidity
  • Heavy cash burn
  • Rising dilution

AI
AI Summary

5.0

TSHA has shifted from a cash-runway story to a binary catalyst trade: its $279M cash cushion can bridge the gap, but near-term upside now depends almost entirely on whether TSHA-102 produces a credible REVEAL readout before ongoing burn and dilution pressure per-share value.

ClinicalCatalyst‍
DilutionRisk
Biotech‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

3.5

Key Financial Insights:

  • Strong liquidity
  • Heavy cash burn
  • Rising dilution

TSHA has a strong cash position and near-term solvency, but persistent losses, heavy cash burn, and rising dilution make the stock risky despite ample liquidity.

CashRunway
Dilution

Price Behavior

5.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Fading momentum
  • Broken support
  • $6.00 hold

TSHA rallied through last month but the post-May 6 pullback back below $6.20–$6.30 shows fading momentum and leaves $6.00 as the key level to hold for the bullish case to stay intact.

TSHA
Pullback
Support Level: $6.00
Resistance Level: $6.20-$6.30

Breakout lost traction after

Sentiment & News

5.0

Key News Insights:

  • TSHA-102 progress
  • Q1 disclosure
  • Hiring retention

Taysha's latest updates highlight encouraging TSHA-102 preclinical progress alongside routine Q1 reporting and employee equity grants, reinforcing steady pipeline execution and normal corporate cadence.

The news is modestly supportive as it signals continued scientific advancement while maintaining operational transparency